To evaluate the potential effect of PTEN/TSC1/TSC2 mutations and integrate the results with the differentiation state of tumor cells, we performed IHC analyses for mTORC1 activation (phospho-S6 Ser240/244). The gene discussed is TSC2; the disease is neoplasm.